Aimed Alliance submitted a comment to the Oregon Prescription Drug Affordability Board (PDAB) urging it to maintain a careful, evidence-based approach as it conducts affordability reviews. The letter raises concerns about the Board’s accelerated timeline and the volume of drugs being reviewed at once, warning that rushing could compromise decision quality and public trust, and encouraged the Board to adopt a thoughtful, replicable process that centers on patient experience, ensuring robust review, and supporting sustainable outcomes for future affordability determinations. Read the letter.
Last Updated on October 1, 2025 by Aimed Alliance
